A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Exclusion Criteria

• •History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
• •History or presence of GI, renal, hepatic disease.
• •Previous or planned bariatric surgery or fitting of a weight loss device.
• •Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
• •History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
• •HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
• •Significant gastric and hepatobiliary disease.
• •History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening.
• •History of psychosis or bipolar disorder.
• •History of major depressive disorder within the 2 years prior to screening or depression.
• •Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.
• •Vulnerable populations